plunge
Zenas BioPharma Shares Plummet After Phase 3 INDIGO Trial for Obexelimab in IgG4-Related Disease Meets Endpoint but Falls Short of Expectations
Zenas BioPharma; obexelimab; Phase 3 INDIGO; IgG4-related disease; share plunge; Amgen Uplizna
Ironwood Pharmaceuticals’ Stock Plummets Following Layoffs and FDA Setback for Apraglutide
Ironwood Pharmaceuticals , apraglutide , short bowel syndrome (SBS) , Phase III trial , layoffs , FDA regulatory hurdle , stock plunge , strategic alternatives , Goldman Sachs , biotechnology